High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: A single centre prospective phase II study

British Journal of Haematology

Volumn 127, Issue 5, 2004, Pages 543-551

  Perz, Jolanta B ^a   Schonland, Stefan O ^a   Hundemer, Michael ^a   Kristen, Arnt V ^a   Dengler, Thomas J ^a   Zeier, Martin ^a   Linke, Reinhold P ^b   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Adriamycin and dexamethasone (VAD); Autologous stem cell transplantation; High dose melphalan; Light chain amyloidosis; Vincristine

Indexed keywords

AMYLOID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAND MAL SEIZURE; HEART ARRHYTHMIA; HUMAN; MALE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SUDDEN DEATH; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 10344245014     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05232.x     Document Type: Article

References (27)

1. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. The New England Journal of Medicine, 310, 1353-1356.
2. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
3. Comenzo, R.L., Vosburgh, E., Falk, R.H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L.M., Berk, J.L., Akpek, G., LaValley, M., O'Hara, C., Arkin, C.F., Wright, D.G. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 3662-3670.
4. Comezo, R.L. & Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 4276-4282.
5. Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Journal of Clinical Oncology, 19, 3350-3356.
6. Dispenzieri, A., Kyle, R.A., Lacy, M.Q., Therneau, T.M., Larson, D.R., Plevak, M.F., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A. & Gertz, M.A. (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood, 103, 3960-3963.
7. Falk, R.H., Comenzo, R.L. & Skinner, M. (1997) The systemic amyloidosis. The New England Journal of Medicine, 337, 898-909.
8. van Gameren, I.I., Hazenberg, B.P., Jager, P.L., Smit, J.W., Vellenga, E., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (2002) AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloidosis, 9, 165-174.
9. Gertz, M., Lacy, M., Gastineau, D.A., Inwards, D.J., Chen, M.G., Teffei, A., Kyle, R.A. & Litzow, M.R. (2000) Blood stem cell transplantation as therapy for primary systemic amyloidosis. Bone Marrow Transplantation, 26, 963-969.
10. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Gastineau, D.A., Chen, M.G., Ansell, S.M., Inwards, D.J., Micallef, I.N., Tefferi, A. & Litzow, M.R. (2002) Stem cell transplantation for the management of primary systemic amyloidosis. The American Journal of Medicine, 113, 549-555.
11. Gillmore, J.D., Apperley, J.F. & Craddock, C. (1999) High-dose melphalan and stem cell recue for AL amyloidosis. In: Amyloid and Amyloidosis (ed. by R.A. Kyle & M.A. Gertz), CRC Press, Parthenon Publishers.
12. Gono, T., Matsuda, M., Dohi, N., Hoshi, K., Tada, T., Sakashita, K., Koike, K., Aizawa, M. & Ikeda, S. (2003) Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Internal Medicine, 42, 72-77.
13. Kyle, R.A., Linos, A., Mary Beard, C., Linke, R.P., Gertz, M.A., O'Fallon, M. & Kurland, L.T. (1992) Incidence and natural history of primary systemic amyloidosis (AL) in Olmsted Country, Minnesota: 1950-1989. Blood, 79, 1817-1822.
14. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. The New England Journal of Medicine, 336, 1202-1207.
15. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1999) Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood, 93, 1062-1066.
16. Linke, R.P. (2000) Highly sensitive diagnosis of amyloid and variuos amyloid syndromes using congo red fluorescence. Virchows Archiv, 436, 439-448.
17. Mehta, J. (2004) High-dose therapy for amyloidosis: the end of the beginning. Blood, 103, 3612-3613.
18. Moreau, P., Leblond, V. & Baurquelot, P. (1998) Prognostic factors of survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766.
19. Palladini, G., Anesi, E., Perfetti, V., Obici, L., Invernizzi, R., Balduini, C., Ascari, E. & Merlini, G. (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 113, 1044-1046.
20. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936-2938.
21. Perfetti, V., Ubbiali, P., Magni, M., Colli Vignarelli, M., Casarini, S., Matteucci, P., Gianni, A.M. & Merlini, G. (1998) Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplantation, 23, 323-327.
22. Sanchorawala, V., Wright, D.G., Seidin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. & Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381-388.
23. Sezer, O., Schmid, P., Schweigen, M., Heider, U., Eucker, J., Harder, H., Sinha, P., Radtke, H. & Possinger, K. (1999) Rapid reversal of nephrotic syndrome due to primary sytemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplantation, 23, 967-969.
24. Skinner, M., Anderson, J.J. & Simms, R. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. The American Journal of Medicine, 100, 290-298.
25. Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O'Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. & Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 85-93.
26. Zeier, M., Perz, J., Linke, R.P., Donini, U., Waldherr, R., Andrassy, K., Ho, A.D. & Goldschmidt, H. (2003) No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrology, Dialysis, Transplantation, 18, 2644-2647.
27. Zenhausern, R., Tobler, A., Leoncini, L., Hess, O.M. & Ferrari, P. (2000) Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide- cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Annals of Hematology, 79, 523-526.